Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | MMP8 | P22894 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28040139 | 0.82 | THRB (0.63) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL525854 | 0.82 | LMNA (0.56) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL3689756 | 0.81 | SMN1; SMN2 (0.49) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL3313643 | 0.79 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL6582665 | 0.79 | LMNA (0.52) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL7449135 | 0.79 | POLB (0.63) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL30802296 | 0.78 | SMN1; SMN2 (0.51) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL7339506 | 0.77 | LMNA (0.61) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL184778 | 0.77 | LMNA (0.61) | LMNASMN1; SMN2POLBTHRBATM | |
| SCHEMBL19279385 | 0.77 | LMNA (0.50) | LMNASMN1; SMN2POLBTHRBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468635-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2016-10-18 | — | — | US | disclosed |
| US-20150126501-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2015-05-07 | — | — | US | disclosed |
| US-8946279-B2 | Fused ring compound for use as mineralocorticoid receptor antagonist | KBP BIOSCIENCES CO., LTD. (CN) | 2015-02-03 | — | — | US | disclosed |
| US-20130289029-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NOVO NORDISK A/S (DK) | 2013-10-31 | — | — | US | disclosed |
| EP-2607363-A1 | FUSED RING COMPOUND FOR USE AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP Biosciences Co., Ltd. (CN) | 2013-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289029-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NR3C2, REN, MC2R | LMNA 1201/4885SMN1; SMN2 4523/4885POLB 3223/4885 |
| US-20150126501-A1 | Fused Ring Compound For Use As Mineralocorticoid Receptor Antagonist | NR3C2, REN, MC2R | LMNA 1201/4885SMN1; SMN2 4523/4885POLB 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.